Voyager Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$29,578
$19,516
$90,061
$4,614
Gross Profit
28,186
18,320
88,726
3,669
EBITDA
-13,633
-14,987
55,398
-28,562
EBIT
-15,025
-16,183
54,063
-29,507
Net Income
-10,141
-11,330
56,395
-25,901
Net Change In Cash
29,578
19,516
90,061
4,614
Free Cash Flow
-32,547
56,626
-26,617
-21,833
Cash
76,127
143,078
68,802
65,269
Basic Shares
57,721
57,117
45,078
43,864

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$250,008
$40,907
$37,415
$171,128
Gross Profit
245,567
40,907
37,415
62,375
EBITDA
126,455
-44,646
-68,453
31,201
EBIT
122,014
-50,837
-73,618
27,384
Net Income
132,330
-46,408
-66,032
36,741
Net Change In Cash
250,008
40,907
37,415
171,128
Cost of Revenue
-18,738
12,993
19,442
Free Cash Flow
74,663
-15,000
-55,134
-108,813
Cash
68,802
98,959
117,433
104,440
Basic Shares
44,569
38,356
37,668
37,348

Earnings Calls

Quarter EPS
2024-06-30
-$0.18
2024-03-31
-$0.20
2023-12-31
$1.25
2023-09-30
-$0.59